Serving as a 'gateway,' Cambridge venture investor closes $300M second fund
For a world-renowned and storied academic institution with multiple Nobel laureates and top-notch biomedical researchers to boast, the University of Cambridge is behind a disproportionately small number of prominent — not to mention world-leading — life sciences companies.
Cambridge Innovation Capital set out almost nine years ago to change that. The goal was simple: It would take the cutting-edge science coming out of the Cambridge ecosystem, which includes not just the university but also a hospital system and several affiliated research institutions, and provide spinouts with the money, talent and network they need to succeed. Specifically, it aimed to be the preferred Series A investor for any life science companies emerging out of the city (it also invests in deep tech companies).
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,600+ biopharma pros reading Endpoints daily — and it's free.